Construction has officially commenced on a $100 million purpose-built facility for a pharmaceutical company — Noumed Pharmaceuticals — based within Terre Property Partners’ Nexus North Industrial Estate in South Australia.
The initiative will increase Australia’s independence in terms of supplying pharmaceutical drugs to pharmacies and health networks since it will manufacture some over-the-counter pharmaceutical goods in South Australia instead of importing them from overseas.
The manufacturing facility, which is being constructed on a 43,000 square metre plot with a 26,000 square metre floor area, will be located in Terre Property Partners’ Nexus North Industrial Estate alongside several other notable domestic and international businesses, such as Asahi, Telstra, Haighs Chocolates and FJT Logistics.
Noumed Managing Director Mark Thulborne expressed the company’s excitement about reaching its goal of bringing manufacturing back to Australia and investing more in South Australia.
“By coming back to Australia, current and future clients can have the comfort that many of their products are being made in South Australia.
“This means a shorter lead time to their shelves and a supplier that can react quickly to their individual needs.”
The new manufacturing plant will receive up to $20 million in funding from the Australian government and is a key part of the state’s 10-year health and medical industries strategy.
The project is expected to create 250 jobs during construction and Noumed will employ more than 180 people when local production begins in 2026.
SA Trade and Investment Minister Nick Champion said: “South Australia’s advanced manufacturing and health ecosystems are ideal for the establishment of Noumed Pharmaceutical’s first hi-tech Australian manufacturing facility at Salisbury.”
Champion stated that this state has an ideal mix of skills and capabilities to make pharmaceutical manufacturing profitable for the next generation of pharmaceutical companies.
“Noumed’s operations in South Australia will boost Australia’s sovereign capability for critical pharmaceutical products, as well as help drive down the cost of generic drugs on the Pharmaceutical Benefits Scheme and healthcare costs for all Australians.”
TMX and FDC also contributed to the overall design and development of this project.
